169 related articles for article (PubMed ID: 12945944)
1. P53 and MIB-1 immunohistochemistry as predictors of the clinical behavior of nonfunctioning pituitary adenomas.
Hentschel SJ; McCutcheon lE; Moore W; Durity FA
Can J Neurol Sci; 2003 Aug; 30(3):215-9. PubMed ID: 12945944
[TBL] [Abstract][Full Text] [Related]
2. Ki-67 labeling index and expression of p53 are non-predictive for invasiveness and tumor size in functional and nonfunctional pituitary adenomas.
Grimm F; Maurus R; Beschorner R; Naros G; Stanojevic M; Gugel I; Giese S; Bier G; Bender B; Honegger J
Acta Neurochir (Wien); 2019 Jun; 161(6):1149-1156. PubMed ID: 31037500
[TBL] [Abstract][Full Text] [Related]
3. [Significance of p53 protein expression and proliferative potential with MIB-1 on tumor recurrence of pituitary adenomas].
Miyagami M; Nakamura S
No To Shinkei; 1998 Jan; 50(1):27-32. PubMed ID: 9493195
[TBL] [Abstract][Full Text] [Related]
4. Flow cytometric DNA ploidy and cells phase fractions in recurrent human pituitary adenomas. A correlative study of flow cytometric analysis and the expression of proliferating cell nuclear antigen.
Chae YS; Flotte T; Hsu DW; Preffer F; Hedley-Whyte ET
Gen Diagn Pathol; 1996 Oct; 142(2):89-95. PubMed ID: 8950573
[TBL] [Abstract][Full Text] [Related]
5. [Non-functioning pituitary adenomas: clinical features and immunohistochemistry].
Ferreira JE; de Mello PA; de Magalhães AV; Botelho CH; Naves LA; Nosé V; Schmitt F
Arq Neuropsiquiatr; 2005 Dec; 63(4):1070-8. PubMed ID: 16400431
[TBL] [Abstract][Full Text] [Related]
6. Mdm2 and the p53 pathway in human pituitary adenomas.
Suliman M; Royds J; Cullen D; Timperley W; Powell T; Battersby R; Jones TH
Clin Endocrinol (Oxf); 2001 Mar; 54(3):317-25. PubMed ID: 11298083
[TBL] [Abstract][Full Text] [Related]
7. Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas.
Saeger W; Lüdecke B; Lüdecke DK
Exp Clin Endocrinol Diabetes; 2008 Feb; 116(2):80-5. PubMed ID: 18072009
[TBL] [Abstract][Full Text] [Related]
8. Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients.
Del Basso De Caro M; Solari D; Pagliuca F; Villa A; Guadagno E; Cavallo LM; Colao A; Pettinato G; Cappabianca P
Neurosurg Rev; 2017 Jan; 40(1):105-114. PubMed ID: 27215912
[TBL] [Abstract][Full Text] [Related]
9. Implications of the World Health Organization definition of atypia on surgically treated functional and non-functional pituitary adenomas.
Sarkar S; Philip VJ; Cherukuri SK; Chacko AG; Chacko G
Acta Neurochir (Wien); 2017 Nov; 159(11):2179-2186. PubMed ID: 28573325
[TBL] [Abstract][Full Text] [Related]
10. Pathobiology of pituitary adenomas and carcinomas.
Scheithauer BW; Gaffey TA; Lloyd RV; Sebo TJ; Kovacs KT; Horvath E; Yapicier O; Young WF; Meyer FB; Kuroki T; Riehle DL; Laws ER
Neurosurgery; 2006 Aug; 59(2):341-53; discussion 341-53. PubMed ID: 16883174
[TBL] [Abstract][Full Text] [Related]
11. Ki-67 expression for predicting progression of postoperative residual pituitary adenomas: correlations with clinical variables.
Matsuyama J
Neurol Med Chir (Tokyo); 2012; 52(8):563-9. PubMed ID: 22976139
[TBL] [Abstract][Full Text] [Related]
12. Subcellular localization of basic fibroblast growth factor and fibroblast growth factor receptor 1 in pituitary adenomas.
Fukui S; Otani N; Nawashiro H; Yano A; Nomura N; Miyazawa T; Ohnuki A; Tsuzuki N; Katoh H; Ishihara S; Shima K
Brain Tumor Pathol; 2002; 19(1):23-9. PubMed ID: 12455885
[TBL] [Abstract][Full Text] [Related]
13. Proliferation markers in different types of clinically non-secreting pituitary adenomas.
Schreiber S; Saeger W; Lüdecke DK
Pituitary; 1999 May; 1(3-4):213-20. PubMed ID: 11081200
[TBL] [Abstract][Full Text] [Related]
14. Recurrence in pituitary adenomas in childhood and adolescence.
Espay AJ; Azzarelli B; Williams LS; Bodensteiner JB
J Child Neurol; 2001 May; 16(5):364-7. PubMed ID: 11392522
[TBL] [Abstract][Full Text] [Related]
15. Clinical features and growth fractions of pituitary adenomas.
Yonezawa K; Tamaki N; Kokunai T
Surg Neurol; 1997 Nov; 48(5):494-500. PubMed ID: 9352815
[TBL] [Abstract][Full Text] [Related]
16. Histopathologic features and MIB-1 labeling indices in recurrent and nonrecurrent meningiomas.
Abramovich CM; Prayson RA
Arch Pathol Lab Med; 1999 Sep; 123(9):793-800. PubMed ID: 10458826
[TBL] [Abstract][Full Text] [Related]
17. Plurihormonality of pituitary adenomas in light of immunohistochemical studies.
Pawlikowski M; Kunert-Radek J; Radek M
Endokrynol Pol; 2010; 61(1):63-6. PubMed ID: 20205106
[TBL] [Abstract][Full Text] [Related]
18. The Prognostic Roles of the Ki-67 Proliferation Index, P53 Expression, Mitotic Index, and Radiological Tumor Invasion in Pituitary Adenomas.
Hasanov R; Aydoğan Bİ; Kiremitçi S; Erden E; Güllü S
Endocr Pathol; 2019 Mar; 30(1):49-55. PubMed ID: 30610566
[TBL] [Abstract][Full Text] [Related]
19. Recurrences of Pituitary Adenomas or Second De Novo Tumors: Comparisons with First Tumors.
Saeger W; Müller M; Buslei R; Flitsch J; Fahlbusch R; Buchfelder M; Knappe UJ; Crock PA; Lüdecke DK
World Neurosurg; 2018 Nov; 119():e118-e124. PubMed ID: 30026158
[TBL] [Abstract][Full Text] [Related]
20. Determination of Ki-67 labeling index in pituitary adenomas using MIB-1 monoclonal antibody.
Lath R; Chacko G; Chandy MJ
Neurol India; 2001 Jun; 49(2):144-7. PubMed ID: 11447433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
